Shopping Cart
- Remove All
Your shopping cart is currently empty
CKI-7
Catalog No. T19913Cas No. 1177141-67-1
Alias CKI-7 dihydrochloride, CKI7 dihydrochloride, CKI-7 2HCl, CKI7 2HCl, CKI 7 dihydrochloride, CKI 7 2HCl
CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
CKI-7
Catalog No. T19913Alias CKI-7 dihydrochloride, CKI7 dihydrochloride, CKI-7 2HCl, CKI7 2HCl, CKI 7 dihydrochloride, CKI 7 2HClCas No. 1177141-67-1
CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $193 | In Stock | |
| 2 mg | $259 | In Stock | |
| 5 mg | $382 | In Stock | |
| 10 mg | $573 | In Stock | |
| 25 mg | $922 | In Stock | |
| 50 mg | $1,250 | In Stock | |
| 100 mg | $1,690 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $418 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CKI-7"
Abemaciclib
Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedSodium salicylate
Salicylic acid sodium salt, 2-Hydroxybenzoic acid sodium salt
T033554-21-7
Sodium salicylate (2-Hydroxybenzoic acid sodium salt), a metabolite of acetylsalicylic acid, can inhibit NF-kB and reduce oxidative stress.
- $45
Size
QTY
Sodium Oxamate Cited
SO, Oxamic acid sodium salt, oxamate sodium, Aminooxoacetic acid sodium salt
T19831565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
- $31
Size
QTY
CitedRibociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Thiazovivin Cited
T21551226056-71-8
Thiazovivin, a ROCK inhibitor (IC50: 0.5 μM), increases the survival rate of hESC.
- $30
Size
QTY
CitedY-27632 dihydrochloride Cited
Y-27632 2HCl
T1725129830-38-2
Y-27632 dihydrochloride (Y-27632 2HCl) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 dihydrochloride also inhibits isolation-induced apoptosis in mouse prostate stem or progenitor cells.
- $39
Size
QTY
CitedDinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedAbemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedRKI-1447
RKI1447
T18981342278-01-6
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2. It has anti-invasive and antitumor activities.
- $47
Size
QTY
Palbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedSelect Batch
Purity:100.00%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1. |
| Targets&IC50 | CK1:6 μM(IC50), CK1:8.5 μM(Ki) |
| Alias | CKI-7 dihydrochloride, CKI7 dihydrochloride, CKI-7 2HCl, CKI7 2HCl, CKI 7 dihydrochloride, CKI 7 2HCl |
| Molecular Weight | 358.67 |
| Formula | C11H14Cl3N3O2S |
| Cas No. | 1177141-67-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/ml (181.23 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy CKI-7 | purchase CKI-7 | CKI-7 cost | order CKI-7 | CKI-7 chemical structure | CKI-7 formula | CKI-7 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.